In this study we genotyped Turkish breast/ovarian cancer patients for BRCA1/BRCA2 mutations: protein truncation test (PTT) for exon 11 BRCA1 of and, multiplex PCR and denaturing gradient gel electrophoresis (DGGE) for BRCA2, complemented by DNA sequencing. In addition, a modified restriction assay w
High incidence of mutations inBRCA1 and BRCA2genes in ovarian cancer
✍ Scribed by T. Yu. Smirnova; N. I. Pospekhova; L. N. Lyubchenko; S. A. Tjulandin; R. F. Gar’kavtseva; E. K. Ginter; A. V. Karpukhin
- Publisher
- Springer US
- Year
- 2007
- Tongue
- English
- Weight
- 271 KB
- Volume
- 144
- Category
- Article
- ISSN
- 0007-4888
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Ovarian cancer is a clinically important cancer in Turkey. The contribution of BRCA1 and BRCA2 to ovarian cancer in Turkish patients has not previously been described. In this study we investigated the presence of BRCA1 and BRCA2 mutations in 102 consecutively ascertained, hospital-based, ovarian ca
Germline mutations in BRCA1 and BRCA2 are associated with increased risks of breast and ovarian cancer. A genome-wide association study (GWAS) identified six alleles associated with risk of ovarian cancer for women in the general population. We evaluated four of these loci as potential modifiers of
A total of 283 epithelial ovarian cancer families from the United Kingdom (UK) and the United States (US) were screened for coding sequence changes and large genomic alterations (rearrangements and deletions) in the BRCA1 and BRCA2 genes. Deleterious BRCA1 mutations were identified in 104 families (